Table 3.
Disease management
| Variable | Saudi Arabia n=206 | Turkey n=199 | Overall n=405 |
|---|---|---|---|
| Lung function test in the last 6 months, n (%) | |||
| Count | 198 | 194 | 392 |
| No | 106 (53.5) | 16 (8.3) | 122 (31.1) |
| Yes | 92 (46.5) | 178 (91.8) | 270 (68.9) |
| Last value of FEV1, n (%) | |||
| Count | 84 | 175 | 259 |
| <30% | 2 (2.4) | 20 (11.4) | 22 (8.5) |
| 30%–50% | 22 (26.2) | 64 (36.6) | 86 (33.2) |
| >50% | 60 (71.4) | 91 (52.0) | 151 (58.3) |
| Last value of FVC, n (%) | |||
| Count | 84 | 174 | 258 |
| <50% | 11 (13.1) | 29 (16.7) | 40 (15.5) |
| 50%–70% | 30 (35.7) | 64 (36.8) | 94 (36.4) |
| >70% | 43 (51.2) | 81 (46.6) | 124 (48.1) |
| Oxygen therapy use in the last 6 months, n (%) | |||
| Count | 195 | 180 | 375 |
| No | 98 (50.3) | 113 (62.8) | 211 (56.3) |
| Yes | 97 (49.7) | 67 (37.2) | 164 (43.7) |
| Treatment class, n (%) | |||
| Count | 206 | 199 | 405 |
| ICS/LABA/LAMA | 156 (75.7) | 151 (75.9) | 307 (75.8) |
| ICS/LABA or ICS/LAMA | 36 (17.5) | 34 (17.1) | 70 (17.3) |
| LAMA or LABA | 8 (3.9) | 10 (5.0) | 18 (4.4) |
| SAMA or SABA | 5 (2.4) | 3 (1.5) | 8 (2.0) |
| Other | 1 (0.5) | 1 (0.5) | 2 (0.5) |
| Number of maintenance treatments (%) | |||
| Count | 206 | 199 | 405 |
| One treatment | 25 (12.1) | 19 (9.6) | 44 (10.9) |
| Two treatments | 81 (39.3) | 87 (43.7) | 168 (41.5) |
| More than two treatments | 100 (48.5) | 93 (46.7) | 193 (47.7) |
| Mean (±SD) | 2.6 (±1.1) | 2.6 (±1.0) | 2.6 (±1.1) |
| Frequency of maintenance treatment, n (%) | |||
| Count | 205 | 199 | 404 |
| Once a day or less | 9 (4.4) | 7 (3.5) | 16 (4.0) |
| Twice a day | 178 (86.8) | 135 (67.8) | 313 (77.5) |
| More than twice a day | 18 (8.8) | 57 (28.6) | 75 (18.6) |
| Type of inhalation device, n (%) | |||
| Metered-dose inhaler | 51 (24.8) | 64 (32.2) | 115 (28.4) |
| Dry powder inhaler | 177 (85.9) | 183 (92.0) | 360 (88.9) |
| Nebulizer | 22 (10.7) | 27 (13.6) | 49 (12.1) |
| Other | 71 (34.5) | 51 (25.6) | 122 (30.1) |
Notes: Disease management characteristics of the study population. The treatment class “other” includes ICS alone, and ICS and methylxanthine. The type of inhalation device “other” includes capsule, diskus, handihaler, inhaler capsule, injection, mask, nasal, nasal pillow, oral, spray, subcutaneous, subcutaneous injection, subcutanous, tablet, turbuhaler, vaccine, and nasal spray.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting beta agonist; SAMA, short-acting muscarinic antagonist.